补充褪黑素缓解铁超载地中海贫血患者骨密度下降和循环氧化应激

IF 8.3 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Pokpong Piriyakhuntorn, Adisak Tantiworawit, Mattabhorn Phimphilai, Tawika Kaewchur, Piangrawee Niprapan, Bhumrapee Srivichit, Nattayaporn Apaijai, Krekwit Shinlapawittayatorn, Nipon Chattipakorn, Siriporn C. Chattipakorn
{"title":"补充褪黑素缓解铁超载地中海贫血患者骨密度下降和循环氧化应激","authors":"Pokpong Piriyakhuntorn,&nbsp;Adisak Tantiworawit,&nbsp;Mattabhorn Phimphilai,&nbsp;Tawika Kaewchur,&nbsp;Piangrawee Niprapan,&nbsp;Bhumrapee Srivichit,&nbsp;Nattayaporn Apaijai,&nbsp;Krekwit Shinlapawittayatorn,&nbsp;Nipon Chattipakorn,&nbsp;Siriporn C. Chattipakorn","doi":"10.1111/jpi.70055","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Thalassemia patients often exhibit low bone mineral density (BMD). The iron overload associated with thalassemia elevates oxidative stress levels, leading to reduced BMD. Melatonin improves BMD in postmenopausal osteopenia, however, its effect on BMD in thalassemia patients with iron overload has not been investigated. A randomized controlled study was conducted at Hematology Clinic, Faculty of Medicine, Chiang Mai University. Thalassemia patients with osteopenia and iron overloaded condition, as indicated by BMD Z-score &lt;−2 at <span>l</span>-spine, femoral neck, or total hip, and serum ferritin level &gt; 500 μg/L were recruited in this study. Patients were randomized to receive either melatonin 20 mg/day or placebo at bedtime for 12 months. BMD was re-evaluated 12 months after interventions. Bone turnover markers (BTM), malondialdehyde (MDA as an oxidative stress marker), and pain scores were assessed at baseline, 6, and 12 months. The outcomes, including BMD, BTM, MDA, and pain scores, were evaluated in all patients. Forty-one thalassemia patients (18 males) were enrolled in the study and randomly assigned to either the melatonin group (<i>n</i> = 21) or the placebo group (<i>n</i> = 20). Characteristics of patients were not differences between groups. Mean age was 30.8 ± 6.2 years old. Thirty-three patients (80.4%) were transfusion-dependent patients. At 12 months, mean BMD at <span>l</span>-spine in melatonin group was not significantly different from placebo group (<i>p</i> = 0.069). However, <span>l</span>-spine BMD at 12 months in the melatonin group was significantly greater than baseline (<i>p</i> = 0.029). Serum levels of P1NP and MDA were significantly reduced at 6 months compared to baseline following melatonin treatment. The melatonin group experienced a notable decrease in back pain scores after 12 months compared to the initial measurements. 20 mg daily melatonin supplementation for 12 months alleviated <span>l</span>-spine BMD loss in iron-overloaded thalassemia with low BMD. Melatonin also significantly reduced circulating oxidative stress and mitigated back pain in these patients.</p>\n </div>","PeriodicalId":198,"journal":{"name":"Journal of Pineal Research","volume":"77 3","pages":""},"PeriodicalIF":8.3000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Melatonin Supplementation Alleviates Bone Mineral Density Decline and Circulating Oxidative Stress in Iron-Overloaded Thalassemia Patients\",\"authors\":\"Pokpong Piriyakhuntorn,&nbsp;Adisak Tantiworawit,&nbsp;Mattabhorn Phimphilai,&nbsp;Tawika Kaewchur,&nbsp;Piangrawee Niprapan,&nbsp;Bhumrapee Srivichit,&nbsp;Nattayaporn Apaijai,&nbsp;Krekwit Shinlapawittayatorn,&nbsp;Nipon Chattipakorn,&nbsp;Siriporn C. Chattipakorn\",\"doi\":\"10.1111/jpi.70055\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Thalassemia patients often exhibit low bone mineral density (BMD). The iron overload associated with thalassemia elevates oxidative stress levels, leading to reduced BMD. Melatonin improves BMD in postmenopausal osteopenia, however, its effect on BMD in thalassemia patients with iron overload has not been investigated. A randomized controlled study was conducted at Hematology Clinic, Faculty of Medicine, Chiang Mai University. Thalassemia patients with osteopenia and iron overloaded condition, as indicated by BMD Z-score &lt;−2 at <span>l</span>-spine, femoral neck, or total hip, and serum ferritin level &gt; 500 μg/L were recruited in this study. Patients were randomized to receive either melatonin 20 mg/day or placebo at bedtime for 12 months. BMD was re-evaluated 12 months after interventions. Bone turnover markers (BTM), malondialdehyde (MDA as an oxidative stress marker), and pain scores were assessed at baseline, 6, and 12 months. The outcomes, including BMD, BTM, MDA, and pain scores, were evaluated in all patients. Forty-one thalassemia patients (18 males) were enrolled in the study and randomly assigned to either the melatonin group (<i>n</i> = 21) or the placebo group (<i>n</i> = 20). Characteristics of patients were not differences between groups. Mean age was 30.8 ± 6.2 years old. Thirty-three patients (80.4%) were transfusion-dependent patients. At 12 months, mean BMD at <span>l</span>-spine in melatonin group was not significantly different from placebo group (<i>p</i> = 0.069). However, <span>l</span>-spine BMD at 12 months in the melatonin group was significantly greater than baseline (<i>p</i> = 0.029). Serum levels of P1NP and MDA were significantly reduced at 6 months compared to baseline following melatonin treatment. The melatonin group experienced a notable decrease in back pain scores after 12 months compared to the initial measurements. 20 mg daily melatonin supplementation for 12 months alleviated <span>l</span>-spine BMD loss in iron-overloaded thalassemia with low BMD. Melatonin also significantly reduced circulating oxidative stress and mitigated back pain in these patients.</p>\\n </div>\",\"PeriodicalId\":198,\"journal\":{\"name\":\"Journal of Pineal Research\",\"volume\":\"77 3\",\"pages\":\"\"},\"PeriodicalIF\":8.3000,\"publicationDate\":\"2025-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pineal Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jpi.70055\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pineal Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jpi.70055","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

地中海贫血患者通常表现为低骨密度(BMD)。与地中海贫血相关的铁超载会升高氧化应激水平,导致骨密度降低。褪黑素可改善绝经后骨质减少患者的骨密度,但其对地中海贫血伴铁超载患者骨密度的影响尚未被研究。在清迈大学医学院血液学诊所进行了一项随机对照研究。本研究招募以L -脊柱、股骨颈或全髋BMD Z-score <;−2、血清铁蛋白水平>; 500 μg/L为指标的伴有骨质减少和铁超载的地中海贫血患者。患者在12个月内随机接受20毫克/天的褪黑激素或安慰剂。干预12个月后重新评估BMD。在基线、6个月和12个月评估骨转换标志物(BTM)、丙二醛(MDA作为氧化应激标志物)和疼痛评分。对所有患者的结果进行评估,包括BMD、BTM、MDA和疼痛评分。41名地中海贫血患者(18名男性)参加了这项研究,并被随机分配到褪黑素组(n = 21)和安慰剂组(n = 20)。两组患者特征无差异。平均年龄30.8±6.2岁。输血依赖患者33例(80.4%)。12个月时,褪黑素组腰脊柱平均骨密度与安慰剂组无显著差异(p = 0.069)。然而,在12个月时,褪黑素组的l-脊柱骨密度显著高于基线(p = 0.029)。与褪黑激素治疗后的基线相比,血清P1NP和MDA水平在6个月时显著降低。与最初的测量结果相比,褪黑素组在12个月后的背痛评分显著下降。每日补充20毫克褪黑素12个月可减轻低骨密度的铁负荷地中海贫血的l-脊柱骨密度损失。褪黑素还显著降低了循环氧化应激,减轻了这些患者的背痛。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Melatonin Supplementation Alleviates Bone Mineral Density Decline and Circulating Oxidative Stress in Iron-Overloaded Thalassemia Patients

Thalassemia patients often exhibit low bone mineral density (BMD). The iron overload associated with thalassemia elevates oxidative stress levels, leading to reduced BMD. Melatonin improves BMD in postmenopausal osteopenia, however, its effect on BMD in thalassemia patients with iron overload has not been investigated. A randomized controlled study was conducted at Hematology Clinic, Faculty of Medicine, Chiang Mai University. Thalassemia patients with osteopenia and iron overloaded condition, as indicated by BMD Z-score <−2 at l-spine, femoral neck, or total hip, and serum ferritin level > 500 μg/L were recruited in this study. Patients were randomized to receive either melatonin 20 mg/day or placebo at bedtime for 12 months. BMD was re-evaluated 12 months after interventions. Bone turnover markers (BTM), malondialdehyde (MDA as an oxidative stress marker), and pain scores were assessed at baseline, 6, and 12 months. The outcomes, including BMD, BTM, MDA, and pain scores, were evaluated in all patients. Forty-one thalassemia patients (18 males) were enrolled in the study and randomly assigned to either the melatonin group (n = 21) or the placebo group (n = 20). Characteristics of patients were not differences between groups. Mean age was 30.8 ± 6.2 years old. Thirty-three patients (80.4%) were transfusion-dependent patients. At 12 months, mean BMD at l-spine in melatonin group was not significantly different from placebo group (p = 0.069). However, l-spine BMD at 12 months in the melatonin group was significantly greater than baseline (p = 0.029). Serum levels of P1NP and MDA were significantly reduced at 6 months compared to baseline following melatonin treatment. The melatonin group experienced a notable decrease in back pain scores after 12 months compared to the initial measurements. 20 mg daily melatonin supplementation for 12 months alleviated l-spine BMD loss in iron-overloaded thalassemia with low BMD. Melatonin also significantly reduced circulating oxidative stress and mitigated back pain in these patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pineal Research
Journal of Pineal Research 医学-内分泌学与代谢
CiteScore
17.70
自引率
4.90%
发文量
66
审稿时长
1 months
期刊介绍: The Journal of Pineal Research welcomes original scientific research on the pineal gland and melatonin in vertebrates, as well as the biological functions of melatonin in non-vertebrates, plants, and microorganisms. Criteria for publication include scientific importance, novelty, timeliness, and clarity of presentation. The journal considers experimental data that challenge current thinking and welcomes case reports contributing to understanding the pineal gland and melatonin research. Its aim is to serve researchers in all disciplines related to the pineal gland and melatonin.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信